ESC Premium Access

PCSK9 inhibition - cholesterol reduction and beyond

Event: ESC CONGRESS 2017
Topic: Lipids (Epidemiology and Prevention)
Session type: Symposium
Date: 26 August 2017
Time: 11:00 - 12:30

Congress Session

4 presentations in this session

A global view: the rationale for aggresive LDL lowering

Speaker: Professor S. Nissen (Cleveland, US)
Thumbnail

Cholesterol metabolism and the role of PCSK9

Speaker: Professor S. Nicholls (Melbourne, AU)
Thumbnail

Show me the data: clinical efficacy, safety and indications of PCSK9 inhibition

Speaker: Professor J. Jukema (Leiden, NL)
Thumbnail

Are there effects of PCSK9 inhibitors beyond cholesterol lowering?

Speaker: Professor B. Cariou (Nantes, FR)
Thumbnail

4 speakers from this session

Professor Steven E Nissen

Cleveland Clinic Foundation, Cleveland (United States of America)
11 presentations
0 follower

Professor Stephen Nicholls

Monash Heart, Melbourne (Australia)
36 presentations
1 follower

Professor J Wouter Jukema

Leiden University Medical Centre, Leiden (Netherlands (The))
16 presentations
0 follower

Professor Bertrand Cariou

Institut du Thorax, Inserm UMR 1087, Nantes (France)
0 follower

This platform is supported by

logo Novo Nordisk